Furthermore, AYAs more often developed a grade 3–4 hepatitis following anti-PD-1 and anti-CTLA-4 combination treatment when compared to older adults (9 out of 21 versus 36 out of 169, p = 0.03). This evidence concerns the gene CTLA4 and Hepatitis.